| Literature DB >> 32476992 |
Lu Zeng1,2, Xiude Fan1, Xiaoyun Wang1, Huan Deng1, Kun Zhang1, Xiaoge Zhang1, Shan He1,2, Na Li1, Qunying Han1, Zhengwen Liu1.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is the most common liver cancer and the mechanisms of hepatocarcinogenesis remain elusive.Entities:
Keywords: Hepatocellular carcinoma; bioinformatics; database; differentially expressed gene; hub gene; mRNA
Year: 2019 PMID: 32476992 PMCID: PMC7235396 DOI: 10.2174/1389202920666191011092410
Source DB: PubMed Journal: Curr Genomics ISSN: 1389-2029 Impact factor: 2.236
Fig. (3)The number of genes enriched in the top five biological process (BP), molecular function (MF) and cellular component (CC) terms (A) and the circle diagram of the top five GO enriched biological process (BP), molecular function (MF) and cellular component (CC) terms (B).
Fig. (6)Associations of the mRNA expression levels of hub genes with the overall survival of HCC patients. (A) TOP2A; (B) NDC80; (C) CDK1; (D) CCNB1; (E) KIF11; (F) BUB1; (G) CCNB2; (H) CCNA2; (I) TTK. The area around each survival curve represents the confidence interval of the survival curve.
The top 20 up-regulated and down-regulated DEGs aggregated in GSE45267, GSE60502 and GSE74656.
|
|
|
|
|
|---|---|---|---|
| NDC80 | 3.81E-08 | FCN3 | 1.16E-08 |
| SPINK1 | 4.89E-07 | HAMP | 1.47E-07 |
| RACGAP1 | 7.81E-06 | APOF | 2.20E-07 |
| ACSL4 | 7.81E-06 | CYP1A2 | 2.64E-07 |
| GINS1 | 1.09E-05 | SLC22A1 | 4.30E-07 |
| PLVAP | 2.10E-05 | CRHBP | 9.44E-07 |
| EZH2 | 4.16E-05 | GYS2 | 9.44E-07 |
| GPC3 | 5.91E-05 | HGFAC | 5.23E-06 |
| CEP55 | 6.25E-05 | AKR1D1 | 6.32E-06 |
| DLGAP5 | 7.43E-05 | CLEC4M | 6.32E-06 |
| CENPE | 8.95E-05 | MT1F | 1.05E-05 |
| CDC20 | 0.00011 | CFHR4 | 1.77E-05 |
| TOP2A | 0.000125 | LPA | 2.09E-05 |
| TTK | 0.000141 | DNASE1L3 | 2.65E-05 |
| KNTC1 | 0.000187 | MT1E | 2.75E-05 |
| ZWILCH | 0.000194 | GNMT | 3.54E-05 |
| NUSAP1 | 0.000258 | KCNN2 | 3.66E-05 |
| CTHRC1 | 0.000258 | CFP | 3.79E-05 |
| SHCBP1 | 0.000278 | CYP2B6 | 4.32E-05 |
| NCAPG | 0.000281 | CYP2E1 | 4.98E-05 |
Abbreviation: DEGs, Differentially Expressed Genes.
The main GO terms of the DEGs aggregated in GSE45267, GSE60502 and GSE74656.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| BP | GO:0022403 | cell cycle phase | 31 | 5.57E-14 | PRC1, NEK2, DBF4, KNTC1, TTK, CEP55, KIF2C, SAC3D1, NCAPG, BUB1, ZWILCH, CCNA2, ASPM, CDCA3, CDC7, CDK1, KIF11, DLGAP5, |
| BP | GO:0000278 | mitotic cell cycle | 29 | 1.45E-13 | PRC1, NEK2, DBF4, KNTC1, TTK, CEP55, KIF2C, SAC3D1, NCAPG, BUB1, ZWILCH, CCNA2, ASPM, CDCA3, CDC7, CDK1, KIF11, DLGAP5, |
| BP | GO:0051301 | cell division | 26 | 2.62E-13 | PRC1, NEK2, KNTC1, CEP55, SAC3D1, NCAPG, BUB1, ZWILCH, CCNA2, ASPM, CDCA3, CDC7, CDK1, KIF11, NUSAP1, CENPE, NDC80, |
| BP | GO:0000280 | nuclear division | 23 | 2.76E-13 | CDK1, KIF11, NEK2, DLGAP5, TPX2, KNTC1, NUSAP1, NDC80, CENPE, CDC20, PBK, CEP55, CCNB1, KIF2C, CCNB2, SAC3D1, NCAPG, |
| BP | GO:0007067 | mitosis | 23 | 2.76E-13 | CDK1, KIF11, NEK2, DLGAP5, TPX2, KNTC1, NUSAP1, NDC80, CENPE, CDC20, PBK, CEP55, CCNB1, KIF2C, CCNB2, SAC3D1, NCAPG, |
| MF | GO:0009055 | electron carrier activity | 21 | 1.35E-11 | CYP3A4, STEAP3, GCDH, CYP2C19, CYP2B6, ADH6, CYP26A1, KMO, CYP4F12, CYP2E1, CYP1A2, CYP4A11, CYP39A1, HAAO, CYP2A6, |
| MF | GO:0019825 | oxygen binding | 11 | 1.78E-10 | CYP3A4, CYP4A11, CYP2C19, CYP2B6, HAAO, CYP26A1, CYP2A7, CYP4F12, CYP2E1, CYP1A2, CYP4F2 |
| MF | GO:0020037 | heme binding | 13 | 7.11E-08 | CYP3A4, CYP4A11, CYP39A1, CYP27A1, CYP2C19, CYP2B6, CYP26A1, CYP2A6, CYP2A7, CYP4F12, CYP2E1, CYP1A2, CYP4F2 |
| MF | GO:0046870 | cadmium ion binding | 6 | 9.47E-08 | MT1M, MT1E, MT1H, MT1G, MT1X, MT1F |
| MF | GO:0046906 | tetrapyrrole binding | 13 | 1.45E-07 | CYP3A4, CYP4A11, CYP39A1, CYP27A1, CYP2C19, CYP2B6, CYP26A1, CYP2A6, CYP2A7, CYP4F12, CYP2E1, CYP1A2, CYP4F2 |
| CC | GO:0005819 | spindle | 18 | 1.40E-11 | CDK1, KIF4A, KIF11, PRC1, NEK2, DLGAP5, KNTC1, TPX2, NUSAP1, TTK, CENPE, CDC20, CBX1, RACGAP1, SAC3D1, BUB1, BUB1B, ASPM |
| CC | GO:0005792 | microsome | 18 | 2.37E-08 | CYP3A4, AQP9, CYP2C19, CYP2B6, IGFALS, CYP26A1, CYP4F12, CYP2E1, CYP1A2, CYP4A11, CYP39A1, CYP2A6, SORT1, CYP2A7, |
| CC | GO:0042598 | vesicular fraction | 18 | 3.64E-08 | CYP3A4, AQP9, CYP2C19, CYP2B6, IGFALS, CYP26A1, CYP4F12, CYP2E1, CYP1A2, CYP4A11, CYP39A1, CYP2A6, SORT1, CYP2A7, |
| CC | GO:0000777 | condensed chromosome kinetochore | 10 | 7.84E-08 | KIF2C, CENPM, HJURP, KNTC1, BUB1, BUB1B, CENPE, NDC80, CENPK, ZWILCH |
| CC | GO:0000779 | condensed chromosome, centromeric region | 10 | 2.48E-07 | KIF2C, CENPM, HJURP, KNTC1, BUB1, BUB1B, CENPE, NDC80, CENPK, ZWILCH |
Abbreviations: DEGs, Differentially Expressed Genes; BP, Biological Process; MF, Molecular Function; CC, Cellular Component.
The KEGG pathways of the DEGs aggregated in GSE45267, GSE60502 and GSE74656.
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
| 1 | Metabolic pathways | hsa01100 | 38 | 8.71E-12 | ||
| 2 | Cell cycle | hsa04110 | 13 | 1.48E-10 | ||
| 3 | Chemical carcinogenesis | hsa05204 | 10 | 5.45E-09 | ||
| 4 | Retinol metabolism | hsa00830 | 9 | 1.18E-08 | ||
| 5 | Fatty acid degradation | hsa00071 | 8 | 1.36E-08 | ||
| 6 | Metabolism of xenobiotics by cytochrome P450 | hsa00980 | 9 | 2.65E-08 | ||
| 7 | Drug metabolism - cytochrome P450 | hsa00982 | 8 | 2.46E-07 | ||
| 8 | Tyrosine metabolism | hsa00350 | 6 | 1.13E-06 | ||
| 9 | p53 signaling pathway | hsa04115 | 7 | 3.51E-06 | ||
| 10 | Mineral absorption | hsa04978 | 6 | 9.06E-06 | ||
| 11 | Progesterone-mediated oocyte maturation | hsa04914 | 7 | 2.80E-05 | ||
| 12 | Caffeine metabolism | hsa00232 | 3 | 3.15E-05 | ||
| 13 | Glycolysis / Gluconeogenesis | hsa00010 | 6 | 3.43E-05 | ||
| 14 | Tryptophan metabolism | hsa00380 | 5 | 3.66E-05 | ||
| 15 | Oocyte meiosis | hsa04114 | 7 | 0.0001 | ||
| 16 | Linoleic acid metabolism | hsa00591 | 4 | 0.000182 | ||
| 17 | Steroid hormone biosynthesis | hsa00140 | 5 | 0.000216 | ||
| 18 | Arachidonic acid metabolism | hsa00590 | 5 | 0.000286 | ||
| 19 | Prion diseases | hsa05020 | 4 | 0.000313 | ||
| 20 | Bile secretion | hsa04976 | 5 | 0.000448 | ||
| 21 | PPAR signaling pathway | hsa03320 | 5 | 0.000505 | ||
| 22 | Primary bile acid biosynthesis | hsa00120 | 3 | 0.000594 | ||
| 23 | Complement and coagulation cascades | hsa04610 | 5 | 0.00071 | ||
| 24 | Drug metabolism - other enzymes | hsa00983 | 4 | 0.000815 | ||
| 25 | Melanoma | hsa05218 | 4 | 0.004018 | ||
| 26 | AMPK signaling pathway | hsa04152 | 5 | 0.004832 | ||
| 27 | FoxO signaling pathway | hsa04068 | 5 | 0.006584 | ||
| 28 | HTLV-I infection | hsa05166 | 7 | 0.007323 | ||
| 29 | Valine, leucine and isoleucine degradation | hsa00280 | 3 | 0.008979 | ||
The HCC enrichment gene sets in GSE45267 by GSEA database.
|
|
|
|
|
|
|---|---|---|---|---|
| MITOTIC_SPINDLE | 1.611 | 0.002 | 0.214 | TTK, NDC80, RACGAP1, KIF4A, PRC1, |
| G2M_CHECKPOINT | 1.553 | 0.004 | 0.125 | TTK, NDC80, CDKN3, RACGAP1, KIF4A, |
| E2F_TARGETS | 1.540 | 0.004 | 0.070 | GINS1, CDKN3, RACGAP1, KIF4A, TOP2A, |
| SPERMATOGENESIS | 1.550 | 0.020 | 0.097 | TTK, CDKN3, EZH2, NEK2, AURKA, |
| DNA_REPAIR | 1.578 | 0.032 | 0.151 | ZWINT, RFC4, PRIM1, SAC3D1, FEN1, |
Abbreviations: NES, Enrichment Score; NOM p-val, Normal p value; FDR, False Discovery Rate Value.